Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announced that investors with losses in Unicycive Therapeutics (UNCY) may seek lead-plaintiff status in an ongoing securities fraud class action, with a deadline of November 2, 2026. The complaint alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturing vendor's facility for current good manufacturing practices compliance, and therefore lacked a reasonable basis to believe FDA-cited deficiencies had been resolved. Per the allegations, those gaps created an undisclosed risk that the FDA would require additional information and that approval of OLC would be delayed.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.